1. Cell Cycle/DNA Damage
    PI3K/Akt/mTOR
  2. DNA-PK

DNA-PK

DNA-PKcs (DNA-dependent protein kinase, catalytic subunit) is an enzyme that in humans is encoded by the PRKDC gene. DNA-PKcs belongs to the phosphatidylinositol 3-kinase-related kinase protein family. DNA-PKcs is the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase called DNA-PK. The second component is the autoimmune antigen Ku. On its own, DNA-PKcs is inactive and relies on Ku to direct it to DNA ends and trigger its kinase activity. DNA-PKcs is required for the non-homologous end joining (NHEJ) pathway of DNA repair. Many proteins have been identified as substrates for the kinase activity of DNA-PK. Autophosphorylation of DNA-PKcs appears to play a key role in NHEJ and is thought to induce a conformational change that allows end processing enzymes to access the ends of the double-strand break. DNA-PK also cooperates with ATR and ATM to phosphorylate proteins involved in the DNA damage checkpoint.

DNA-PK Related Products (15):

Cat. No. Product Name Effect Purity
  • HY-10197
    Wortmannin Inhibitor 99.65%
    Wortmannin is a multi-target inhibitor of PI3K and MLCK with IC50s of 3 nM and 200 nM, respectively. Wortmannin is also a potent inhibitor of DNA-PK (IC50, 16 nM) and ATM (IC50, 150 nM). Wortmannin is also a potent inhibitor of Polo-like kinase (Plk).
  • HY-11006
    KU-57788 Inhibitor 99.35%
    KU-57788 is a potent and selective inhibitor of DNA-PK, with an IC50 of 13 nM, and also increases CRISPR/Cas9-mediated editing frequencies.
  • HY-12513
    LY3023414 Inhibitor 99.70%
    LY3023414 potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations.
  • HY-13002
    Torin 2 Inhibitor 99.89%
    Torin 2 is an mTOR inhibitor with EC50 of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC50: 200 nM). Torin 2 also inhibits DNA-PK with an IC50 of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.
  • HY-15719
    NU 7026 Inhibitor 99.95%
    NU 7026 is a novel specific DNA-PK inhibitor with IC50 of 0.23±0.01 μM, also inhibits PI3K with IC50 of 13±3 μM.
  • HY-103709S
    VX-984 Inhibitor
    VX-984 is a selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 of 88±64 nM for A549 lung cancer cells.
  • HY-13281
    PIK-75 Inhibitor 99.91%
    PIK-75 is a DNA-PK and PI3K inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM).
  • HY-101570
    M3814 Inhibitor 99.43%
    M3814 is a potent and selective inhibitor of DNA-dependent Protein Kinase (DNA-PK).
  • HY-16962
    CC-115 Inhibitor
    CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
  • HY-101667
    LTURM34 Inhibitor 99.24%
    LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM.
  • HY-101146
    SF2523 Inhibitor 99.37%
    SF2523 is a highly selective and potent inhibitor of PI3K with IC50s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.
  • HY-12030
    PIK-90 Inhibitor 99.06%
    PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.
  • HY-16962A
    CC-115 hydrochloride Inhibitor
    CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
  • HY-19341
    Compound 401 Inhibitor 99.88%
    Compound 401 is a synthetic inhibitor of DNA-PK (IC50 = 0.28 μM) that also targets mTOR but not PI3K in vitro.
  • HY-19977
    YU238259 Inhibitor 98.01%
    YU238259 is an inhibitor of homology-dependent DNA repair (HDR), used for cancer research.